Page 73 - Read Online

Page 52 Tarantino et al. Cancer Drug Resist 2019;2:43-52 I http://dx.doi.org/10.20517/cdr.2018.22

31. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. KRAS mutation status is predictive of response to cetuximab therapy in
colorectal cancer. Cancer Res 2006;66:3992-5.
32. Storer BE. An evaluation of phase I clinical trial designs in the continuous dose-response setting. Stat Med 2001;20:2399-408.
33. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, et al. Translation of innovative designs into phase I trials. J Clin Oncol
2007;25:4982-6.
34. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1
monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015;21:4286-93.
35. Lindauer A, Valiathan CR, Mehta K, Sriram V, de Greef R, et al. Translational pharmacokinetic/pharmacodynamic modeling of tumor
growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab. CPT Pharmacometrics Syst Pharmacol
2017;6:11-20.
36. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open 2017;2:e000279.
37. Guo B, Yuan Y. Bayesian phase I/II biomarker-based dose finding for precision medicine with molecularly targeted agents. J Am Stat
Assoc 2017;112:508-20.
38. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors
of success in phase III. J Clin Oncol 2008;26:1346-54.
39. Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 2010;5:932-4.
40. Neel DS, Bivona TG. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ Precis Oncol
2017;1:3.
41. Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-
mutation detected by circulating tumour DNA. Ann Oncol 2017;28:784-90.
42. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, et al. Clonal evolution and resistance to EGFR blockade in the blood of
colorectal cancer patients. Nat Med 2015;21:795-801.
43. Goodall J, Mateo J, Yuan W, Mossop H, Porta N, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP
inhibition. Cancer Discov 2017;7:1006-17.
44. Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: understanding tumor heterogeneity
and real time monitoring of early resistance to targeted therapies. Pharmacol Ther 2016;157:120-4.
45. Pon JR, Marra MA. Driver and passenger mutations in cancer. Annu Rev Pathol Mech Dis 2015;10:25-50.
46. Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, et al. A framework to rank genomic alterations as targets for
cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol 2018;29:1895-902.
47. Ellis L. The elusive search for biomarkers of anti-VEGF activity. Mol Diagnostics Cancer Ther Dev 2007;13:PL06-01.
48. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847-56.
49. Singh RR, Luthra R, Routbort MJ, Patel KP, Medeiros LJ. Implementation of next generation sequencing in clinical molecular
diagnostic laboratories: advantages, challenges and potential. Expert Rev Precis Med Drug Dev 2016;1:109-20.
50. Pennell NA. Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations
in metastatic non-small cell lung cancer using a decision analytic model. J Clin Oncol 2018;36:9031.
51. André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC):
results of the phase 3 SOLAR-1 trial. Available from: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Alpelisib-
ALP-fulvestrant-FUL-for-advanced-breast-cancer-ABC-results-of-the-Phase-3-SOLAR-1-trial. [Last accessed on 27 Feb 2019]